# Mark Cole

Mark Cole writes about quality and regulatory compliance in medical device manufacturing. Cole's posts connect FDA warning letters and ISO 13485 requirements to practical decisions, including how manufacturers should validate automated processes and oversee AI-generated documents.

- Profile: https://b2binfluencer.marketing/creators/mark-cole/
- LinkedIn: https://www.linkedin.com/in/mark-cole-04a50313
- LinkedIn followers: 978
- Topics: artificial-intelligence, leadership
- Based on 9 dated posts, latest 2026-10-05

## Summary

Mark Cole is most useful for explaining medical device quality and regulatory compliance through FDA warning letters and ISO 13485.

- Best for: A medical device manufacturer strengthening quality compliance, preparing for FDA inspection, or governing AI in documentation.
- Not for: A direct-to-consumer wellness brand or general AI productivity brand seeking large-scale consumer awareness.
- Check first: Confirm audience breakdown, recent performance data, rates, and a direct inquiry route.

### Takeaways

- AI can write compliance documents, but a qualified person still owns them.
- Automated inspection needs validation, guardrails, and a human backstop.
- Quality leadership is a competence question that FDA inspections actually test.

## Main ideas

- **AI can write the documents, but a qualified person still owns them**: Cole's central point: AI agents may help produce specifications, procedures, and production records, but the manufacturer is accountable for their contents. Qualified personnel, not the tool, must approve specifications and procedures. In pharmaceutical manufacturing, 21 CFR 211.22(c) assigns the quality control unit responsibility for approving or rejecting specifications affecting identity, strength, quality, and purity. They argue the same discipline applies to device makers through ISO 13485, under which various processes require review and approval by qualified personnel. When an AI agent misses a legal requirement, the resulting noncompliance is the company's, not the agent's, to resolve.
- **Automated inspection is fine only with validation, guardrails, and a human backstop**: Cole treats automation as a compliance question, not just an efficiency one. Component inspection using electronic imaging and software can check far more parts than human inspectors, but a process not verified through later monitoring or measurement must be validated under ISO 13485 7.5.6. They distinguish validation from verification, explain the condition that determines which is required, and identify the controls that keep a validated system trustworthy. The organization remains responsible for whether the product meets specification, regardless of the automated system's conclusion.
- **Quality leadership is a competence question that inspections actually test**: Cole argues that appointing someone with no quality assurance background to lead Quality is a bad hire, especially in small start-ups where one person shapes the whole quality strategy. The argument rests on ISO 13485 Section 6.2, which requires personnel doing work that affects product quality to be competent on the basis of appropriate education, training, skills, and experience. They also point to inspection practice: inspectors ask for the documentation that supports this competence requirement.
- **Tests an outside argument against device rules**: Cole takes a specific text—a regulator's letter or someone else's article—and works out what it means for device manufacturers, naming the applicable clause rather than offering general commentary. When another writer's position enters their posts, they credit it and distinguish its limits from their own conclusion.

## Work to read

- [A warning letter shows what happens when AI writes the compliance documents](https://www.linkedin.com/posts/mark-cole-04a50313_warning-letter-that-references-inappropriate-activity-7451025722116321281-iJOa)
- [Reading an Oracle article on AI judgment through a device-manufacturing lens](https://www.linkedin.com/posts/mark-cole-04a50313_this-week-i-read-an-article-in-forbes-written-activity-7453531881020555265-opyv)
- [Why an inexperienced head of Quality is a bad hire before an FDA inspection](https://www.linkedin.com/posts/mark-cole-04a50313_the-importance-of-hiring-an-experienced-head-activity-7493763457947873280-K36P)

## Partnerships

Mark Cole's posts give a brand no partnership menu to work from. The three posts are practitioner commentary on quality and regulatory compliance in medical device and pharmaceutical manufacturing: FDA warning letters, ISO 13485 requirements, AI oversight of documents and production decisions, and the case for experienced quality leadership. None contains a sponsored segment, a paid brand mention, an affiliate link, or any stated commercial offer, and no sponsor relationship is disclosed. No media kit, rate card, sponsorship policy, or partnership inquiry route appears in the posts. Ask directly about availability, rates, and partnership terms. The LinkedIn account shows roughly 978 followers as of October 2026, a small audience relative to the depth of the technical commentary — relevant if a plan depends on reach rather than demonstrated compliance expertise.

## Alternatives

- Pawel Olszowy: Choose Pawel Olszowy when a compliance task sits in pharmaceutical or small-molecule manufacturing rather than a medical device quality system. The posts show clause-and-tool-level work on ICH Q12 lifecycle management: Established Conditions that distinguish dossier elements critical to product quality from those manageable through the Pharmaceutical Quality System; Post-Approval Change Management Protocols agreed with regulators in advance; and a Product Lifecycle Management document treated as a living roadmap. A second post covers Process Analytical Technology as more than instruments: validated analytical models, integration with LIMS and MES, and cross-functional ownership across R&D, manufacturing, and QA, with real-time monitoring of critical quality attributes during synthesis, granulation, and tableting. If the manufacturer needs to plan a second site, a new supplier, higher volumes, or a process change without a lengthy CMC exercise, this material addresses the decision more directly than Mark Cole's device-focused posts.
- Josh Neuhart, CCWP: Choose Josh Neuhart when a compliance program is failing on people rather than procedure. The posts offer two repeatable workforce exercises. The first starts with a multi-site staffing problem: if 8 of 200 locations keep asking for help, that is 8 local problems, not a national labor shortage. Neuhart pairs each high-turnover location with a similar well-performing one and compares pay competitiveness within a 10-mile radius, shift times, transportation access for a 5:00 AM start, hiring speed, manager response time, and what happens in a new hire's first week. The second applies the same logic to defense manufacturing: identify who cannot take a week off without risking a delivery, then check who is qualified and authorized for each critical task on the scheduled shift, whether a qualified backup exists, and whether that backup would leave another critical operation uncovered. This question set is useful when a quality unit is fully staffed on paper but a required inspection or sign-off depends on one qualified person.
- Anthony Cacciatore: Choose Anthony Cacciatore when the decision has moved from the quality system to equipment and its connections. One post argues that cybersecurity now belongs in robot selection alongside payload, reach, accuracy, cycle time, price, service, and integration. Robot controllers talk to PLCs and HMIs, connect to MES and ERP, feed cloud platforms, and allow remote access. The post explains IEC 62443-4-2 and Security Level 2 in plain terms, distinguishes a manufacturer's claim that a product is cyber-secure from independent certification, and tells buyers to ask the manufacturer, the integrator, and for the certificate. A second post frames increased Canadian defence spending as a manufacturing modernization opportunity: traceability, quality control, cybersecurity, production consistency, and scalability requirements will push suppliers toward automation. The argument is that the measure of the investment should be what Canada builds as well as what it buys. If the campaign is about the automation roadmap, connected-factory purchasing, or the defence supply chain rather than the compliance document trail, Cacciatore is closer to the subject.

---
AI-assisted summary of public posts. Audience demographics are not available. Engagement appears only where we checked recent posts. Method: https://b2binfluencer.marketing/methodology/